Live Breaking News & Updates on Yair Lotan

Stay updated with breaking news from Yair lotan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

UTSW Research: Improved bladder cancer detection,

UTSW Research: Improved bladder cancer detection,
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

United States , Ashutosh Shukla , Yuxiao Sun , Peter Odonnell Jr , Usman Hyder , Yair Lotan , Ivan Dorso , Conan Juan , Michael Woodard , Ashwini Challa , Benjamin Levi , Lin Xu , Nader Pouratian , School Of Public Health , Brain Institute , Bone Research , Senior Research Scientist , Research Assistants , Haroldc Simmons Comprehensive Cancer Center , Senior Research Scientists Heeseog Kang , African American , Urologic Oncology , Comprehensive Cancer Center , Neural Engineering , Neurological Surgery , Petero Donnell ,

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location

RFS Was 100% in Patients who Received Maintenance. ....

United States , San Antonio , Adam Feldman , Urogen Rtgel , Mark Schoenberg , Yair Lotan , Urogen Pharma , Urogen Pharma Ltd , Department Of Urology At Massachusetts , Parkland Health , American Urological Association Meeting , Urologic Oncologist , Massachusetts General Hospital , Combined Harvard Urologic Oncology , Urologic Oncology , Hospital System , Chief Medical Officer , Upper Tract Urothelial Cancer , Prescribing Information , Patient Information , Private Securities Litigation Reform Act , Risk Factors , Annual Report ,

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer – IT Business Net

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United States , University Of Texas , Anirudh Joshi , Clausg Roehrborn , Stephenb Williams , Viswesh Krishna , Yair Lotan , Damir Vrabac , Ut Southwestern Medical Center , University Of Texas Medical Branch , Meeting Of The American Urological Association , Innovative New Diagnostic Test , Guide First Line Treatment Decisions , Valar Labs , American Urological Association , Urologic Oncology , John Justin Distinguished Chair , Bacillus Calmette Guerin , Associate Chief Medical Officer , Texas Medical ,

Phase 4 study evaluating real-world use of ADSTILADRIN® (nadofaragene filadenovec-vncg)

Phase 4 study evaluating real-world use of ADSTILADRIN® (nadofaragene filadenovec-vncg)
independantexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from independantexpress.com Daily Mail and Mail on Sunday newspapers.

United States , University Of Southern California , San Francisco , Nadofaragene Filadenovec , Dalila Delatorre , Siamek Daneshmand , Kristen Litchfield , Yair Lotan , Thea Daneshmand , Amy Guo , Christian Juhl , Sandra Guedes , National Comprehensive Cancer Network , Ferring Pharmaceuticals , Drug Administration , Fering Pharmaceuticals , American Cancer Society , Noris Comprehensive Cancer Center , Annual Genitourinary Cancer Symposium , World Evidence , American Society , Bacillus Calmette Gu , Caregiving Adapted Work Productivity , Activity Impairment , Initial Utilization , Real World ,

Outcomes of Bladder-Sparing Therapy for BCG-Unresponsive NMIBC Worsen Over Time

“Patients need to be monitored closely with a low threshold for rebiopsy to detect recurrences as early as possible so that other treatments can be offered,” said investigator Yair Lotan, MD. A study determined the oncologic risks of bladder-sparing therapy over time in BCG-unresponsive bladder cancer. ....

United States , Yair Lotan , Society Of Urologic Oncology , Ut Southwestern Medical Center , Bacillus Calmette Gu , Urologic Oncology , Annual Meeting , Medical Center ,